Design of the tocilizumab in giant cell arteritis trial

International Journal of Rheumatology

Volumn 2013, Issue , 2013, Pages

  Unizony, Sebastian H ^a   Dasgupta, Bhaskar ^b   Fisheleva, Elena ^c   Rowell, Lucy ^c   Schett, Georg ^d   Spiera, Robert ^e   Zwerina, Jochen ^d   Harari, Olivier ^c   Stone, John H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SOUTHEND HOSPITAL   (United Kingdom)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; PLACEBO; PREDNISONE; TOCILIZUMAB;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; GIANT CELL ARTERITIS; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SAMPLE SIZE; STUDY DESIGN;

EID: 84877259423     PISSN: 16879260     EISSN: 16879279     Source Type: Journal    
DOI: 10.1155/2013/912562     Document Type: Article

References (62)

1. Gonzalez-Gay M. A., Vazquez-Rodriguez T. R., Lopez-Diaz M. J., Miranda-Filloy J. A., Gonzalez-Juanatey C., Martin J., Llorca J., Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Care and Research 2009 61 10 1454 1461 2-s2.0-70349768112 10.1002/art.24459
2. Salvarani C., Crowson C. S., O'Fallon W. M., Hunder G. G., Gabriel S. E., Reappraisal of the epidemiology of giant cell arteritis in olmsted county, minnesota, over a fifty-year period. Arthritis Care and Research 2004 51 2 264 268 2-s2.0-1842679462 (Pubitemid 38468712)
3. Lawrence R. C., Felson D. T., Helmick C. G., Arnold L. M., Choi H., Deyo R. A., Gabriel S., Hirsch R., Hochberg M. C., Hunder G. G., Jordan J. M., Katz J. N., Kremers H. M., Wolfe F., Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis and Rheumatism 2008 58 1 26 35 2-s2.0-38149052992 10.1002/art.23176
4. Lee J. L., Naguwa S. M., Cheema G. S., Gershwin M. E., The geo-epidemiology of temporal (giant cell) arteritis. Clinical Reviews in Allergy and Immunology 2008 35 1-2 88 95 2-s2.0-55249088546 10.1007/s12016-008-8075-0
5. Weyand C. M., Goronzy J. J., Giant-cell arteritis and polymyalgia rheumatica. Annals of Internal Medicine 2003 139 6 505 515 2-s2.0-0141574199
6. Borg F. A., Salter V. L. J., Dasgupta B., Neuro-ophthalmic complications in giant cell arteritis. Current Allergy and Asthma Reports 2008 8 4 323 330 2-s2.0-50349097687 10.1007/s11882-008-0052-4
7. Proven A., Gabriel S. E., Orces C., Michael O'Fallon W., Hunder G. G., Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Care and Research 2003 49 5 703 708 2-s2.0-0142063451 (Pubitemid 37296477)
8. Salvarani C., Cantini F., Boiardi L., Hunder G. G., Polymyalgia rheumatica and giant-cell arteritis. The New England Journal of Medicine 2002 347 4 261 271 2-s2.0-0037173470 10.1056/NEJMra011913 (Pubitemid 34787634)
9. De Vita S., Tavoni A., Jeracitano G., Gemignani G., Dolcher M. P., Bombardieri S., Treatment of giant cell arteritis with cyclophosphamide pulses. Journal of Internal Medicine 1992 232 4 373 375 2-s2.0-0026733295
10. Schaufelberger C., Andersson R., Nordborg E., No additive effect of cyclosporin a compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. British Journal of Rheumatology 1998 37 4 464 465 2-s2.0-0031854423 (Pubitemid 28372209)
11. De Silva M., Hazleman B. L., Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Annals of the Rheumatic Diseases 1986 45 2 136 138 2-s2.0-0022578244 (Pubitemid 16162481)
12. Jover J. A., Hernández-García C., Morado I. C., Vargas E., Bañares A., Fernàndez-Gutiérrez B., Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 2001 134 2 106 114 2-s2.0-0035895218 (Pubitemid 32096337)
13. Spiera R. F., Mitnick H. J., Kupersmith M., Richmond M., Spiera H., Peterson M. G. E., Paget S. A., A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clinical and Experimental Rheumatology 2001 19 5 495 501 2-s2.0-0034837581 (Pubitemid 32894598)
14. Hoffman G. S., Cid M. C., Hellmann D. B., Guillevin L., Stone J. H., Schousboe J., Cohen P., Calabrese L. H., Dickler H., Merkel P. A., Fortin P., Flynn J. A., Locker G. A., Easley K. A., Schned E., Hunder G. G., Sneller M. C., Tuggle C., Swanson H., Hernández-Rodríguez J., Lopez-Soto A., Bork D., Hoffman D. B., Kalunian K., Klashman D., Wilke W. S., Scheetz R. J., Mandell B. F., Fessler B. J., Kosmorsky G., Prayson R., Luqmani R. A., Nuki G., McRorie E., Sherrer Y., Baca S., Walsh B., Ferland D., Soubrier M., Choi H. K., Gross W., Segal A. M., Ludivico C., Puechal X., A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis and Rheumatism 2002 46 5 1309 1318 2-s2.0-0036090211 10.1002/art.10262 (Pubitemid 34525840)
15. Hoffman G. S., Cid M. C., Rendt-Zagar K. E., Merkel P. A., Weyand C. M., Stone J. H., Salvarani C., Xu W., Visvanathan S., Rahman M. U., Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis a randomized trial. Annals of Internal Medicine 2007 146 9 621 630 2-s2.0-34248351219 (Pubitemid 351650517)
16. Martínez-Taboada V. M., Rodríguez-Valverde V., Carreño L., López-Longo J., Figueroa M., Belzunegui J., Mola E. M., Bonilla G., A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Annals of the Rheumatic Diseases 2008 67 5 625 630 2-s2.0-42449142953 10.1136/ard.2007.082115 (Pubitemid 351571925)
17. Seitz M., Reichenbach S., Bonel H. M., Adler S., Wermelinger F., Villiger P. M., Rapid induction of remission in large vessel vasculitis by IL-6 blockade: a case series. Swiss Medical Weekly 2011 141 w13156 2-s2.0-79955751346 10.4414/smw.2011.13156
18. Sciascia S., Rossi D., Roccatello D., Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. The Journal of Rheumatology 2011 38 9 2080 2081 10.3899/jrheum.110496
19. Beyer C., Axmann R., Sahinbegovic E., Distler J. H., Manger B., Schett G., Zwerina J., Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Annals of the Rheumatic Diseases 2011 70 10 1874 1875 10.1136/ard.2010.149351
20. Salvarani C., Magnani L., Catanoso M., Pipitone N., Versari A., Dardani L., Pulsatelli L., Meliconi R., Boiardi L., Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology 2012 51 1 151 156
21. Vinit J., Bielefeld P., Muller G., Besancenot J. F., Efficacy of tocilizumab in refractory giant cell arteritis. Joint Bone Spine 2012 79 3 317 318 10.1016/j.jbspin.2011.11.008
22. Unizony S., Arias-Urdaneta L., Miloslavsky E., Arvikar S., Khosroshahi A., Keroack B., Stone: J., Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, takayasu arteritis) and polymyalgia rheumatica. Arthritis Care & Research 2012 64 11 1720 1729 10.1002/acr.21750
23. Lurati A., Bertani L., Re K. A., Marrazza M., Bompane D., Scarpellini: M., Successful treatment of a patient with giant cell vasculitis (horton arteritis) with tocilizumab a humanized anti-interleukin-6 receptor antibody. Case Reports in Rheumatology 2012 2012 2 639612 10.1155/2012/639612
24. Isik M., Kilic L., Dogan I., Calguneri: M., Tocilizumab for giant cell arteritis: an amazing result. Rheumatology International. In press
25. Besada E., Nossent: J. C., Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab. Clinical Rheumatology 2012 31 8 1263 1265
26. Smolen J. S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., Woodworth T., Alten R., Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. The Lancet 2008 371 9617 987 997 2-s2.0-40749114497 10.1016/S0140-6736(08)60453-5 (Pubitemid 351392039)
27. Genovese M. C., McKay J. D., Nasonov E. L., Mysler E. F., Da Silva N. A., Alecock E., Woodworth T., Gomez-Reino J. J., Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis and Rheumatism 2008 58 10 2968 2980 2-s2.0-54949150604 10.1002/art.23940
28. Emery P., Keystone E., Tony H. P., Cantagrel A., Van Vollenhoven R., Sanchez A., Alecock E., Lee J., Kremer J., IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Annals of the Rheumatic Diseases 2008 67 11 1516 1523 2-s2.0-52149099504 10.1136/ard.2008.092932
29. Jones G., Sebba A., Gu J., Lowenstein M. B., Calvo A., Gomez-Reino J. J., Siri D. A., Tomšič M., Alecock E., Woodworth T., Genovese M. C., Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Annals of the Rheumatic Diseases 2010 69 1 88 96 2-s2.0-73449118587 10.1136/ard.2008.105197
30. Weyand C. M., Younge B. R., Goronzy J. J., IFN- γ and IL-17: the two faces of T-cell pathology in giant cell arteritis. Current Opinion in Rheumatology 2011 23 1 43 49 2-s2.0-78650509945 10.1097/BOR.0b013e32833ee946
31. Wagner A. D., Goronzy J. J., Weyand C. M., Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. Journal of Clinical Investigation 1994 94 3 1134 1140 2-s2.0-0028030811
32. Deng J., Younge B. R., Olshen R. A., Goronzy J. J., Weyand C. M., Th17 and th1 T-cell responses in giant cell arteritis. Circulation 2010 121 7 906 915 2-s2.0-77649157249 10.1161/CIRCULATIONAHA.109.872903
33. Terrier B., Geri G., Chaara W., Allenbach Y., Rosenzwajg M., Costedoat-Chalumeau N., Fouret P., Musset L., Benveniste O., Six A., Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis & Rheumatism 2012 64 6 2001 2011
34. Espigol-Frigole G., Corbera-Bellalta M., Planas-Rigol E., Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Annals of the Rheumatic Diseases. In press
35. Samson M., Audia S., Fraszczak J., Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis & Rheumatism 2012 64 11 3788 3798 10.1002/art.34647
36. Naka T., Nishimoto N., Kishimoto: T., The paradigm of IL-6: from basic science to medicine. Arthritis Research & Therapy 2002 4 3 S233 S242
37. Miossec P., Korn T., Kuchroo V. K., Interleukin-17 and type 17 helper T cells. The New England Journal of Medicine 2009 361 9 848 898 2-s2.0-69349093225 10.1056/NEJMra0707449
38. Sakaguchi S., Miyara M., Costantino C. M., Hafler D. A., FOXP3+ regulatory T cells in the human immune system. Nature Reviews Immunology 2010 10 7 490 500 2-s2.0-77954141914 10.1038/nri2785
39. Weyand C. M., Hicok K. C., Hunder G. G., Goronzy J. J., Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Annals of Internal Medicine 1994 121 7 484 491 2-s2.0-0028597540
40. Emilie D., Liozon E., Crevon M. C., Lavignac C., Portier A., Liozon F., Galanaud P., Production of interleukin 6 by granulomas of giant cell arteritis. Human Immunology 1994 39 1 17 24 2-s2.0-0028271191 10.1016/0198-8859(94)90096-5 (Pubitemid 24152731)
41. Visvanathan S., Rahman M. U., Hoffman G. S., Xu S., Garcia-Martinez A., Segarra M., Lozano E., Espigol-Frigole G., Hernandez-Rodriguez J., Cid M. C., Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis-a prospective longitudinal study. Rheumatology 2011 50 11 2061 2070
42. García-Martínez A., Hernández-Rodríguez J., Espígol-Frigolé G., Prieto-González S., Butjosa M., Segarra M., Lozano E., Cid M. C., Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care and Research 2010 62 6 835 841 2-s2.0-77953087545 10.1002/acr.20043
43. Dasgupta B., Panayi G. S., Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. British Journal of Rheumatology 1990 29 6 456 458 2-s2.0-0025645940
44. Weyand C. M., Fulbright J. W., Hunder G. G., Evans J. M., Goronzy J. J., Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis & Rheumatism 2000 43 5 1041 1048 (Pubitemid 30368181)
45. Roche N. E., Fulbright J. W., Wagner A. D., Hunder G. G., Goronzy J. J., Weyand C. M., Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis and Rheumatism 1993 36 9 1286 1294 2-s2.0-0027380872 10.1002/art.1780360913 (Pubitemid 23303119)
46. Fujimoto M., Serada S., Mihara M., Uchiyama Y., Yoshida H., Koike N., Ohsugi Y., Nishikawa T., Ripley B., Kimura A., Kishimoto T., Naka T., Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis and Rheumatism 2008 58 12 3710 3719 2-s2.0-57349083145 10.1002/art.24126
47. Serada S., Fujimoto M., Mihara M., Koike N., Ohsugi Y., Nomura S., Yoshida H., Nishikawa T., Terabe F., Ohkawara T., Takahashi T., Ripley B., Kimura A., Kishimoto T., Naka T., IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America 2008 105 26 9041 9046 2-s2.0-48249148236 10.1073/pnas. 0802218105
48. Haruta H., Ohguro N., Fujimoto M., Hohki S., Terabe F., Serada S., Nomura S., Nishida K., Kishimoto T., Naka T., Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Investigative ophthalmology & visual science 2011 52 6 3264 3271 2-s2.0-79961008060
49. Korn T., Mitsdoerffer M., Croxford A. L., Awasthi A., Dardalhon V. A., Galileos G., Vollmar P., Stritesky G. L., Kaplan M. H., Waisman A., Kuchroo V. K., Oukka M., IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America 2008 105 47 18460 18465 2-s2.0-57449112782 10.1073/pnas.0809850105
50. Brack A., Rittner H. L., Younge B. R., Kaltschmidt C., Weyand C. M., Goronzy J. J., Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. Journal of Clinical Investigation 1997 99 12 2842 2850 2-s2.0-0030961240 (Pubitemid 27278659)
51. Evans J. M., Bowles C. A., Bjornsson J., Mullany C. J., Hunder G. G., Thoracic aortic aneurysm and rupture in giant cell arteritis: a descriptive study of 41 cases. Arthritis and Rheumatism 1994 37 10 1539 1547 2-s2.0-0028116423 10.1002/art.1780371020 (Pubitemid 24337700)
52. Narváez J., Bernad B., Roig-Vilaseca D., García- Gómez C., Gómez-Vaquero C., Juanola X., Rodriguez-Moreno J., Nolla J. M., Valverde J., Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Seminars in Arthritis and Rheumatism 2007 37 1 13 19 2-s2.0-34447640192 10.1016/j.semarthrit.2006.12.005 (Pubitemid 47087885)
53. García-Martínez A., Hernández-Rodríguez J., Arguis P., Paredes P., Segarra M., Lozano E., Nicolau C., Ramírez J., Lomeña F., Josa M., Pons F., Cid M. C., Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Care and Research 2008 59 3 422 430 2-s2.0-40849116298 10.1002/art.23315 (Pubitemid 351399213)
54. Nuenninghoff D. M., Hunder G. G., Christianson T. J. H., McClelland R. L., Matteson E. L., Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis and Rheumatism 2003 48 12 3532 3537 2-s2.0-0348111229 10.1002/art.11480 (Pubitemid 37531920)
55. Lie J. T., Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Seminars in Arthritis and Rheumatism 1995 24 6 422 431 2-s2.0-0029031570 10.1016/S0049-0172(95)80010-7
56. Gonzalez-Gay M. A., Garcia-Porrua C., Piñeiro A., Pego-Reigosa R., Llorca J., Hunder G. G., Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine 2004 83 6 335 341 2-s2.0-9144233221 10.1097/01.md.0000145366. 40805.f8 (Pubitemid 39541110)
57. Mukhtyar C., Guillevin L., Cid M. C., Dasgupta B., De Groot K., Gross W., Hauser T., Hellmich B., Jayne D., Kallenberg C. G. M., Merkel P. A., Raspe H., Salvarani C., Scott D. G. I., Stegeman C., Watts R., Westman K., Witter J., Yazici H., Luqmani R., EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases 2009 68 3 318 323 2-s2.0-61449178959 10.1136/ard.2008.088351
58. Dasgupta B., Borg F. A., Hassan N., Alexander L., Barraclough K., Bourke B., Fulcher J., Hollywood J., Hutchings A., James P., Kyle V., Nott J., Power M., Samanta A., BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology 2010 49 8 1594 1597 2-s2.0-77954720405 10.1093/rheumatology/keq039a keq039a
59. Hunder G. G., Bloch D. A., Michel B. A., Stevens M. B., Arend W. P., Calabrese L. H., Edworthy S. M., Fauci A. S., Leavitt R. Y., Lie J. T., Lightfoot R. W., Masi A. T., McShane D. J., Mills J. A., Wallace S. L., Zvaifler N. J., The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis and Rheumatism 1990 33 8 1122 1128 2-s2.0-0025103002 (Pubitemid 20273297)
60. Blockmans D., Bley T., Schmidt W., Imaging for large-vessel vasculitis. Current Opinion in Rheumatology 2009 21 1 19 28 2-s2.0-58149252181 10.1097/BOR.0b013e32831cec7b
61. Janssen S. P., Comans E. H., Voskuyl A. E., Wisselink W., Smulders Y. M., Giant cell arteritis: heterogeneity in clinical presentation and imaging results. Journal of Vascular Surgery 2008 48 4 1025 1031 2-s2.0-55149090085 10.1016/j.jvs.2008.04.054
62. Martinez-Lado L., Calviño-Díaz C., Piñeiro A., Dierssen T., Vazquez-Rodriguez T. R., Miranda-Filloy J. A., Lopez-Diaz M. J., Blanco R., Llorca J., Gonzalez-Gay M. A., Relapses and recurrences in giant cell arteritis: A population-based study of patients with biopsy-proven disease from Northwestern Spain. Medicine 2011 90 3 186 193 2-s2.0-79955581949 10.1097/MD.0b013e31821c4fad